Sonen Capital
101 Montgomery Street, Suite 2150, San Francisco, CA, 94104, United States
Overview
Sonen Capital is a dedicated impact investment management firm. Their name is derived from Social and Environmental investing and reflects their values and their conviction that investing to generate financial returns and lasting social and environmental impact are not only compatible but also mutually reinforcing objectives. With over five decades of combined sustainable investing learning and experience, Sonen team members are field builders dedicated to helping mobilize financial assets to help meet large-scale global challenges. This deep experience serves not only to inform and improve Their knowledge and understanding of this evolving area, but it also enhances. Their ability to deliver to their clients increasingly more sophisticated and holistic impact investing solutions.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 1
- Active investors
- 8
Sector focus
- Advice
- Financial Services
- Impact Investing
Investment portfolio
- Biomakers
Participated · Series A · Jan 2026
BIOMAKERS, headquartered in San Francisco, has built an integrated precision oncology ecosystem that combines large-scale molecular diagnostics, longitudinal real-world clinical data, and a deeply annotated tumor biobank. Its AI-native platform links genomic insights directly to patient samples and clinical outcomes, equipping life-science partners with intelligence to de-risk R&D, broaden trial access, and speed decision-making across the drug-development lifecycle. The company operates in more than 20 countries and runs clinical laboratories in Mexico, Brazil, and Argentina, giving it reach into diverse and under-sampled patient populations. BIOMAKERS’ tumor biobank exceeds 100,000 cases, and the firm maintains direct longitudinal connections to patients, physicians, and healthcare institutions. Having spent years assembling this infrastructure, it is now focused on scaling and monetizing the platform by deploying proprietary AI that structures and harmonizes electronic medical record data. This strategy positions BIOMAKERS as foundational infrastructure for global precision oncology R&D.